$ACTC: Regenerative Profits
by The Dean
Advanced Cell Technology (OTC: ACTC.OB) is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people around the world.
$ACTC focuses on stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to a patient’s beside.
The Dean likes $ACTC because the company’s technologies could unlock treatment for a broad range of diseases, including heart failure, blood disorders, cardiovascular disease, cancer, macular degeneration, hepatitis and even skin conditions.
Currently, $ACTC’s Myoblast program for the treatment of heart failure has successfully completed Phase I human clinical trials. The FDA has reviewed data from the trial and the company plans to proceed with a Phase II clinical trial for the treatment.
CONTINUED @ http://thehonorsclass.com/ACTC